The study is a target trial emulation using observational data, not a randomized clinical trial. While the methods are strong and the findings are compelling, the authors themselves conclude that prospective studies are needed to establish causality. Meta-analyses of randomized controlled trials provide a mixed, but generally reassuring, picture with the pooled signal suggesting either a neutral or modestly protective effect of GLP-1 RAs on fracture risk. Several critical points temper the interpretation of these pooled results though: 1. Fractures were not primary endpoints in any of these RCTs. Fracture events were captured as adverse events, meaning ascertainment was inconsistent and likely incomplete across trials. 2. Very low event rates leave the analyses underpowered to detect clinically meaningful differences with confidence. References Cheng L, et al. Diabetes/Metabolism Research and Reviews. 2019;35(7):e3168. Association of Glucagon-Like Peptide-1 Receptor Agonists Use With Fracture Risk in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials Zhang Y, et al. Bone. 2025;192:117338. Effect of GLP-1 Receptor Agonists on Bone Mineral Density, Bone Metabolism Markers, and Fracture Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis Tan Y, et al. Acta Diabetologica. 2025;62(5):589-606. Glucagon-Like Peptide-1 Receptor Agonists and Fracture Risk: A Network Meta-Analysis of Randomized Clinical Trials #glp1 #bone #bones #health #diabetes